A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
This article was originally published in The Tan Sheet
Executive Summary
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
You may also be interested in...
Claritin 12-Hour Takes Aim At Shorter-Duration Allergy Drugs
Schering-Plough extends the Claritin line into the 12-hour allergy relief niche to go after first-generation antihistamines with shorter durations
Perrigo Predicts Cough/Cold Sales Drop Due To Pseudoephedrine BTC Move
Perrigo's cough/cold sales will likely be hurt in fiscal 2006 as retailers restrict pseudoephedrine products to behind-the-counter sale, according to the firm
Schering Prepares For “Turnaround”; Claritin Falls Flat In First Quarter
Schering-Plough's Claritin experienced another relatively flat quarter despite an increase in promotional spending